Fig 1.
Flow chart of the study population.
Table 1.
Baseline characteristics of the study population.
Fig 2.
Clinical outcomes of incidence rates and relative risks of cardiac events between ACCi and ACSa.
ACCi, aspirin+clopidogrel+cilostazol; ACSa, aspirin+clopidogrel+sarpogrelate; MACCE, major adverse cardiac cerebral events (composite events of death, myocardial infarction, ischemic stroke, revascularization).
Table 2.
Clinical outcomes of Incidence rates and relative risks of cardiac or cerebral events.
Table 3.
Safety outcomes of incidence rates and relative risks of bleeding complications.